Core Insights - The company, Sai Sheng Pharmaceutical, reported that as of September 10, 2025, the number of shareholders is 34,261 [2] Company Summary - Sai Sheng Pharmaceutical has engaged with investors through an interactive platform, providing updates on shareholder numbers [2]

Group 1 - The company, Sai Sheng Pharmaceutical, reported that as of August 29, 2025, the number of shareholders is 34,632 [1]

Market Overview - The biopharmaceutical sector experienced a slight increase of 0.0% on September 12, with Aopumai leading the gains [1] - The Shanghai Composite Index closed at 3883.69, up by 0.22%, while the Shenzhen Component Index closed at 12996.38, up by 0.13% [1] Top Gainers in Biopharmaceutical Sector - Aopumai (688293) closed at 54.00, with a rise of 4.73% and a trading volume of 20,300 lots, totaling a transaction value of 103 million [1] - Kexing Pharmaceutical (688136) closed at 42.28, increasing by 3.45% with a trading volume of 47,400 lots, amounting to 197 million [1] - Sanofi (688336) closed at 57.07, up by 3.39% with a trading volume of 52,600 lots, totaling 294 million [1] - Tibet Pharmaceutical (600211) closed at 56.60, rising by 3.38% with a trading volume of 93,300 lots, totaling 510 million [1] - Wenqu Pharmaceutical (688488) closed at 16.00, increasing by 2.83% with a trading volume of 86,300 lots, amounting to 134 million [1] Top Decliners in Biopharmaceutical Sector - Rongchang Biopharmaceutical (688331) closed at 107.22, down by 2.68% with a trading volume of 56,400 lots, totaling 611 million [2] - Wanze Shares (000534) closed at 16.02, decreasing by 2.61% with a trading volume of 135,500 lots, amounting to 218 million [2] - Kangtai Biopharmaceutical (300601) closed at 18.63, down by 1.48% with a trading volume of 156,700 lots, totaling 292 million [2] Capital Flow Analysis - The biopharmaceutical sector saw a net outflow of 310 million from institutional investors, while retail investors experienced a net inflow of 132 million [2] - Notable net inflows from retail investors were observed in Kanghua Biological (300841) with 94.86 million, and Xizang Pharmaceutical (600211) with 49.76 million [3] - Conversely, significant net outflows were noted in Rongchang Biopharmaceutical (688331) with 17.13 million and Aopumai (688293) with 18.19 million from retail investors [3]

致：北京赛升药业股份有限公司 北京市朝阳区建外大街丁 12 号英皇集团中心 8、9、11 层 8/9/11/F, Emperor Group Centre, No.12D, Jianwai Avenue, Chaoyang District, Beijing, 100022, P.R.China 电话/Tel.: 010-50867666 传真/Fax: 010-56916450 网址/Website: www.kangdalawyers.com 北京 西安 深圳 海口 上海 广州 杭州 沈阳 南京 天津 菏泽 成都 苏州 呼和浩特 香港 武汉 郑州 长沙 厦门 重庆 合肥 宁波 济南 昆明 南昌 北京市康达律师事务所 关于北京赛升药业股份有限公司 2025 年第一次临时股东大会的法律意见书 康达股会字【2025】第 0372 号 3、本所律师同意将本法律意见书作为公司本次会议的必备文件公告，并依法对本 所出具的法律意见承担责任。 本所律师已经对与出具法律意见书有关的所有文件材料进行核查，现场见证了本 次会议并据此出具法律意见如下： 一、本次会议的召集、召开程序 （一）本次会议的召集 根据《中华人民共和国公司 ...

证券代码:300485 证券简称：赛升药业 公告编号：2025-035 北京赛升药业股份有限公司 2025 年第一次临时股东大会决议公告 （一）会议召开情况： 1、会议召集人：公司董事会 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东大会无增加、变更议案的情形。 2、本次股东大会不涉及变更前次股东大会决议的情形。 3、本次股东大会采取现场投票与网络投票相结合的表决方式。 一、会议召开和出席情况 2、会议方式：本次会议采取现场投票和网络投票相结合的方式 3、会议召开时间： （1）现场会议召开时间为：2025 年 9 月 8 日下午 14:30 （2）网络投票时间：通过深圳证券交易所交易系统进行网络投票的具体时 间为 2025 年 9 月 8 日 9:15-9:25、9:30-11:30 和 13:00-15:00；通过互联网投 票系统投票的具体时间为：2025 年 9 月 8 日 9:15-15:00 任意时间。 4、会议地点：北京市北京经济技术开发区兴盛街 8 号 5、会议主持人：董事长马骉先生 6、本次会议的召集、召开符合《公司法》 ...

Group 1 - The biopharmaceutical sector experienced a decline of 0.64% on September 3, with Sai Sheng Pharmaceutical leading the drop [1] - The Shanghai Composite Index closed at 3813.56, down 1.16%, while the Shenzhen Component Index closed at 12472.0, down 0.65% [1] - Notable gainers in the biopharmaceutical sector included Baipu Sais, which rose by 12.10% to a closing price of 65.50, and Yuan Yang Crystal Sea, which increased by 9.14% to 32.95 [1] Group 2 - The net capital outflow from the biopharmaceutical sector was 446 million yuan, while retail investors saw a net inflow of 292 million yuan [3] - The table of individual stock capital flows indicates varying levels of investment activity among different companies within the sector [3]

Group 1 - The latest stock price of Sai Sheng Pharmaceutical is 14.26 yuan, up 0.49% from the previous trading day, with a highest intraday price of 14.34 yuan and a lowest of 14.17 yuan, and a trading volume of 120,780 hands, amounting to 172 million yuan [1] - The company operates in the biopharmaceutical industry, focusing on the research, production, and sales of biological drugs [1] - For the first half of 2025, the company reported total operating revenue of 197 million yuan and a net profit attributable to shareholders of 47.78 million yuan, achieving a turnaround from loss to profit compared to the same period last year [1] - The company's gross profit margin stands at 64.78%, and its asset-liability ratio is maintained at a low level of 4.65% [1] - The latest report indicates that Sai Sheng Pharmaceutical had a net cash inflow from operating activities of 29.34 million yuan for the first half of 2025 [1] - As of August 21, 2025, there are 6 institutional investors holding shares in the company, with a total holding ratio of 1.85%, an increase of 0.86 percentage points from the previous quarter [1] Group 2 - In terms of capital flow, the company experienced a net outflow of 13.98 million yuan from main funds on the day, with a cumulative net outflow of 51.28 million yuan over the past five days [2]

2025年8月22日，赛升药业(300485.SZ)发布2025年中报。 公司最新毛利率为64.78%，较上季度毛利率增加2.56个百分点。最新ROE为1.40%，较去年同期ROE增 加4.57个百分点。 公司摊薄每股收益为0.10元，较去年同报告期摊薄每股收益增加0.32元。 公司最新总资产周转率为0.06次。最新存货周转率为0.84次，较去年同期存货周转率增加0.12次，同比 较去年同期上涨16.05%。 公司股东户数为3.90万户，前十大股东持股数量为2.89亿股，占总股本比例为60.07%，前十大股东持股 情况如下： | 序号 | 股东名称 | 持股比例 | | --- | --- | --- | | I | 司設 | 49.51% | | 2 | 马丽 | 6.20% | | w | 刘淑芹 | 1.82% | | 4 | 中国建设银行股份有限公司-广发科技创新混合型证券投资基金 | 0.48% | | રે | UBS AG | 0.47% | | 6 | 闫大壮 | 0.42% | | 1 | MORGAN STANLEY & CO. INTERNATIONAL PLC. | 0.38% | | ...

Group 1 - The core viewpoint of the news is that Sai Sheng Pharmaceutical (300485.SZ) has reported an increase in institutional and foreign investment holdings as of August 21, 2025, indicating growing interest from investors [1][2] - As of the report date, a total of 6 institutional investors hold shares in Sai Sheng Pharmaceutical, with a combined holding of 8.8971 million shares, representing 1.85% of the total share capital, which is an increase of 0.86 percentage points from the previous quarter [1] - The public funds disclosed during this period include two new funds: GF Technology Innovation Mixed A and Huatai-PineBridge CSI 2000 ETF, while two funds were no longer disclosed: JY Shun'an Yuanqi Flexible Allocation Mixed and Wan Jia Medical Quantitative Stock Selection Mixed Initiation A [1] Group 2 - In terms of foreign investment, one foreign fund, Morgan Stanley & Co. International PLC, increased its holdings by 0.16% compared to the previous quarter [2] - Two new foreign institutions disclosed during this period are UBS AG and Barclays Bank PLC, while Hong Kong Central Clearing Limited and Goldman Sachs LLC were no longer disclosed [2]

Meeting Announcement - Beijing Saiseng Pharmaceutical Co., Ltd. will hold its first extraordinary general meeting of shareholders in 2025 on September 8, 2025, at 14:30 [1] - The meeting will be conducted in a combination of on-site and online voting methods [2] Voting Rights and Registration - All shareholders registered by 15:00 on September 2, 2025, are entitled to attend the meeting, and those unable to attend in person may appoint a proxy [2][3] - Registration for corporate shareholders requires specific documentation, while individual shareholders must present their ID and securities account card [3][4] Voting Process - Shareholders can vote through the Shenzhen Stock Exchange trading system and the internet voting system during the specified voting hours on September 8, 2025 [5][9] - The voting process includes rules for handling duplicate votes, ensuring that the first valid vote is counted [9] Additional Information - The company has provided contact details for inquiries and has outlined the necessary steps for proxy voting and registration [5][6]